Sisram Medical Launches Buyback of Up to 1% of Shares
Hong Kong – October 08, 2026 -- Sisram Medical Ltd (1696.HK) has announced a share repurchase plan to buy back up to 1% of its total issued shares on the open market, citing confidence in its long-term growth trajectory.
Buyback plan allows cancellation or treasury retention of shares
Under the existing share repurchase mandate, repurchased shares may either be cancelled or held as treasury shares depending on future capital management needs. The plan will be executed subject to market conditions, with the Board stating it will balance business development priorities, strategic investment needs and financial flexibility.
First-half 2026 revenue climbs 3.6% to US$171.4 million
Sisram reported H1 2026 revenue of US$171.4 million, up 3.6% year-on-year. International markets excluding North America drove growth, rising 16.7% YoY to US$127.0 million, with APAC generating US$78.4 million, a 19.1% YoY increase.